Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study.

[1]  B. Schurch,et al.  Long‐term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity , 2018, Neurourology and urodynamics.

[2]  G. Karsenty,et al.  Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed , 2018, Neurourology and urodynamics.

[3]  A. Kaviani,et al.  Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. , 2017, The Urologic clinics of North America.

[4]  R. Dmochowski,et al.  Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity , 2017, BJU international.

[5]  G. Holmbeck,et al.  Testing the Utility of a Bio-Neuropsychosocial Model for Predicting Medical Adherence and Responsibility During Early Adolescence in Youth With Spina Bifida , 2016, Journal of pediatric psychology.

[6]  I. bonan,et al.  Outcomes of intra‐detrusor injections of botulinum toxin in patients with spina bifida: A systematic review , 2016, Neurourology and urodynamics.

[7]  M. Chancellor,et al.  Use of Botulinum Toxin in Urologic Diseases. , 2016, Urology.

[8]  P. Marque,et al.  Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity , 2016, Neurourology and urodynamics.

[9]  J. Myers,et al.  Management options for sphincteric deficiency in adults with neurogenic bladder , 2016, Translational andrology and urology.

[10]  P. Marque,et al.  Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity , 2016, World Journal of Urology.

[11]  S. Bauer,et al.  International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children , 2015, Neurourology and urodynamics.

[12]  E. Cheng,et al.  Update on Urological Management of Spina Bifida from Prenatal Diagnosis to Adulthood. , 2015, The Journal of urology.

[13]  A. Wisniewski,et al.  Mental health and parenting characteristics of caregivers of children with spina bifida. , 2015, Journal of pediatric urology.

[14]  I. Yağmur,et al.  Botulinum injection is useless on fibrotic neuropathic bladders. , 2015, Journal of pediatric urology.

[15]  J. Bosch,et al.  Upper and Lower Urinary Tract Outcomes in Adult Myelomeningocele Patients: A Systematic Review , 2012, PloS one.

[16]  M. Brin,et al.  Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. , 2012, The Journal of urology.

[17]  M. Horst,et al.  Repeated botulinum‐a toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele , 2011, Neurourology and urodynamics.

[18]  M. Brin,et al.  Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. , 2011, European urology.

[19]  J. Gajewski,et al.  Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. , 2011, The Journal of urology.

[20]  D. Clayton,et al.  Urologic management of spina bifida. , 2010, Developmental disabilities research reviews.

[21]  J. Hipp,et al.  Microarray analysis of bladder smooth muscle from patients with myelomeningocele , 2008, BJU international.

[22]  X. Gamé,et al.  [Vesicosphincteric and sexual disorders associated with spina bifida and myelomeningocele]. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[23]  P. Dasgupta,et al.  Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. , 2006, European urology.

[24]  Laura E Mitchell,et al.  Spina bifida , 2015, Nature Reviews Disease Primers.

[25]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[26]  B. Schurch,et al.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. , 2000, The Journal of urology.

[27]  A. Rossi,et al.  Spinal dysraphism: a review of neuroradiological features with embryological correlations and proposal for a new classification , 2000, Neuroradiology.